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It is shown that AcSDKP a new regulator of the hematopoietic system can be generated from thymosin f14 by a one-step enzymatic leavage in 
vitro and in vivo. AcSDKP and Tfl4 were both detected in bone marrow cells (BMC). Incubation of [3H]Tfl4 with either intact or lysed BMC led 
to the formation of [3H]AcSDKP whereas the labelled tetrapeptide was not degraded under these conditions. Model enzymatic degradation of
Tfl4 carried out with bacterial enzymes suggests hat a mammalian endoproteinase Asp-N might be involved in the formation of AcSDKP through 
the specific leavage of the 4pro-SAsp eptide bond of Tfl4. 
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1. INTRODUCTION 
Biological ly active peptides are synthesized in cells as 
part  of  relatively high molecular  weight precursors 
which are further processed by specific proteolysis 
before active peptides are generated. We recently 
isolated from fetal calf bone marrow a tetrapept ide Ac- 
N-Ser -Asp-Lys-Pro  (AcSDKP) .  This peptide inhibits in 
vivo the entry into S-phase of  cell populat ions which are 
normal ly  blocked in Go of  the cell cycle. This property  
was demonstrated for mur ine hematopoiet ic  p lur ipo-  
tent stem cells st imulated in vivo by cytosine 
arabinos ide treatment [1], as well as for rat hepatocytes 
tr iggered into S-phase by caseine injection or part ia l  
hepatectomy [2]. 
It was suggested by us [1] that this tetrapept ide might 
derive from thymosin /34 (T/34). This polypept ide is 
presently the only sequenced mammal ian  protein which 
contains the complete sequence of  the acetylated 
tetrapept ide at its N-terminus (Fig. 1) [3]. T/34 was first 
isolated as a thymic hormone from calf  thymus and 
described as an immunomodulatory  factor [4]. 
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In the present paper,  we report  evidence that (i) T/34 
is present as a const ituent of  bone marrow cells (BMC), 
(ii) BMC contain an enzymatic system which leads, star- 
t ing f rom [3H]T/34, to the format ion of  [3H]AcSDKP 
and (iii) that bacterial  endoprote inase Asp-N mimics 
BMC maturat ion  enzyme and forms AcSDKP through 
a one step enzymatic leavage of  T/34. 
2. MATERIALS  AND METHODS 
Flavobacterium eningosepticum ct-prolyl-endopeptidase (EC 
3.4.21.26) was purchased from Seikagaku Kogyo. Asp-N- 
endoproteinase was purchased from Boehringer (Mannheim). T/34 
was isolated from bovine spleen [5]. 
AcSDKP was a generous gift from IPSEN Beaufour. This peptide 
has been specifically tritiated on the lysine residue (Morgat et al., 
1990, Proc. Eur. Pep. Symposium, in press). 
2.1. Isolation of T1~4 from murine BMC 
T/34 extraction was carried out by a one step procedure as previous- 
ly described [6]. An aliquot of the sample was analysed by reverse 
phase HPLC on a Licrospher 5 #m column (4 x 250 mm, Merck, 
Darmstadt, FRG) using a linear gradient of n-propanol (0-40% 
within 60 min) in 0.02 M pyridine/0.1 M formic acid/0.1 M lithium 
perchlorate ata flow rate of 0.75 ml/min. The elution was monitored 
by fluorescence measurement after post-column derivatization f the 
peptides with fluorescamine [7]. 
2.2. 3H-labelling of T~4 by tritium exchange 
T/34 (1.35 mg, 270 nmol) was dissolved in 450/zl of water and then 
frozen. The catalyst (38.4 mg PdO) was added and the reacting vial 
was connected to the tritium supplying automatic device [8]. At 102 
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Fig. 1. Structure of Thymosin/34. 
reverse phase HPLC (Fig. 3). After an 18 h digestion, 200 #1 of the 
sample were separated by a preparative r verse phase HPLC system 
equipped with a sampling valve having an internal chamber (2 #1). The 
sampling valve diverted aliquots of the column effluent into the 
fluram detection system at regular intervals [7]. 
Pa, 1110-1480 GBq (30-40 Ci) of pure tritium gas were introduced 
and compressed to 1.6 x 105 Pa. After thawing, the reaction mixture 
was kept at room temperature and magnetically stirred for 2 h. The 
absorption of tritium gas produced a pressure reduction of 0.85 × 105 
Pa. The catalyst was removed from the reacting solution by filtration 
over a Schlecher and Schuell filter (0.2 #m, FPO30/3) and labile 
tritium atoms were eliminated by successive flash evaporations in
dilute acetic acid (0.507o). Total radioactivity recovered was: 83.62 
MBq (2.26 mCi). The crude labelled material was purified by HPLC 
on a Hypersil C18 column (4 x 250 mm) (SFCC, Neuilly, France) 
with a linear gradient of two solvents A and B (A: 0.1 07o TFA, B: 6007o 
CH3CN with 0.107o TFA, elution pattern: 0 to 1 min, 10007o A, 0.5 
ml/min; l min to 30 min: from 100o70 A to 10007o B, 1 ml/min). Quan- 
titative and comparative estimations indicated that the specific activi- 
ty was found to be around 288.6 GBq/mmol (7.8 Ci/mmol). 
2.3. Degradation of  [3H]Tfl4 and [JH]AcSDKP by rabbit BMC 
Bone marrow from rabbit femur was dissociated in RPMI 1640 
medium supplemented with 2 mM L-glutamine, 100 U/ml penicillin 
and 100 #g/ml streptomycin. Cells were resuspended at 108 cells/ml 
in the same medium. Either radiolabelled [3H]T/34 (150 kBq) or 
[~H]AcSDKP (75 kBq, 4440 GBq mmol) were incubated at 37°C for 
various periods of time with 300/A of either the cell lysate or the intact 
cell suspension. After protein precipitation with trichloracetic acid, 
supernatants were analysed by reverse phase HPLC. 
2.4. Digestion of  Tfl4 by endoproteinase Asp-N 
1 mg T~4 was dissolved in 450 #1 of phosphate buffer (50 mM, pH 
8.0), then 2 #g of endoproteinase Asp-N in 50 #1 water were added. 
The digestion was carried out at room temperature for 18 h. At 
various periods of time, 50 #1 aliquots were analysed by analytical 
3. RESULTS 
3.1. Detection of T~4 in mouse BMC 
Murine BMC perchloric acid extracts (A) were 
analysed by reverse phase HPLC. Spectra exhibited a 
peak at 30.36 min characteristic of the elution time of 
T~4 (Fig. 2a). This peak co-eluted with an authentic 
sample of the polypeptide (Fig. 2b). After an oxidative 
treatment by H202, the 30.36 min peak present in sam- 
ple A was shifted to 28.18 min (Fig. 2c), which cor- 
responded to the elution time of the sulfoxide derivative 
of T/34 formed following this treatment. 
3.2. Degradation of T/34 into AcSDKP by the rabbit 
BMC enzymatic system 
Random labelled [3H]T~4 was prepared from T~4 by 
a catalytic exchange of H2 with 3H2 and incubated for 
various periods of time with rabbit BMC. 
Incubation media were analysed by HPLC. Fractions 
corresponding to AcSDKP were collected between 
19-23 min whereas larger peptidic fragments derived 
from T/~4 and intact T~4 were recovered as a unique 
fraction collected between 30-40 min. After a 2 h in- 
cubation, the highest level of radioactivity associated 
with 19-23 min fraction was reached and corresponded 
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Fig. 2. HPLC analysis of murine BMC extract. BMC were extracted by perchloric acid (sample A). HPLC analysis was carried out with (a) sample 
A, (b) sample A spiked with 2/~g of T/34, (c) sample A oxidized at 37°C with 507o H202 within 60 min. Peak 1 = T/34. 
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Fig. 3. Radioactive AcSDKP is formed by incubation of [3H]T~34 with 
BMC : HPLC analysis of the collected 19-23 min fraction. The col- 
lected 19-23 min fraction (Table I) was lyophilized and reinjected in 
the same conditions. Elution was monitored by UV detection at 215 
nm and by radioactivity measurement of the collected fractions. 
(Table I), i.e. to about 50070 of the radioactivity 
theoretically associated with the N-terminal AcSDKP 
fragment of T/34. This amount was unchanged after an 
Table 1 
Degradation of [3H]T/34 by rabbit BMC enzymatic system 
Percentage of the total radioactivity 
associated with the corresponding fraction 
Incubation time 
Collected fractions 0 1 h 2 h 18 h 
19-23 min 0 2.5 5.0 4.0 
30-40 min 100 91.5 77.1 78.6 
[3H]Tfl4 was incubated for various periods of time with intact rabbit 
BMC. Soluble fraction was coinjected with 10/~g of AcSDKP and 
separated by reverse phase HPLC. Analysis was performed at a flow 
rate of I ml/min on a Hypersil C18 column (4 x 250 mm, SFCC) first 
with 4.5070 CHaCN, 0.1 TFA for 28 min and then with a gradient from 
4.507o CH3CN, 0.1070 TFA to 0.1 TFA in CH3CN for 5 min. Elution 
was monitored by UV detection at 215 nm and by radioactivity 
measurement of the collected fractions previously lyophilised and 
resuspended in 2.5 ml of a scintillation liquid (ACS, Amersham, Les 
Ulis, France). Fractions corresponding to AcSDKP were collected 
between 19-23 min whereas larger peptidic fragments derived from 
T~4 and intact T/~4 were recovered between 30-40 min in a unique 
fraction. 
18 h incubation period. Comparative experiments car- 
ried out with rabbit BMC lysate led after a 2 h incuba- 
tion period, to the recovery of a maximal 0.9°70 of the 
total radioactivity into the 19-23 min fraction, i.e. to 
about 10070 of the radioactivity heoretically associated 
with the N-terminal AcSDKP fragment of T/34. Longer 
incubation periods did not lead to the recovery of a 
larger amount of radioactivity in the 19-23 min frac- 
tion. For the two types of experiment, when the 19-23 
min fraction was reanalysed by HPLC the radioactivity 
coeluted with added unlabelled AcSDKP (Fig. 3). 
3.3. Degradation of [3H]AcSDKP by rabbit BMC 
enzymatic system 
After a 4 h incubation of [3H]AcSDKP with either in- 
tact rabbit BMC or their lysate, 97070 of the radioactivi- 
ty was recovered in the 19-23 min fraction, i.e. in the 
elution peak of the tetrapeptide. 
3.4. Degradation of Tfl4 by bacterial endoproteinase 
Asp-N 
Treatment of T/34 by endoproteinase Asp-N led to the 
formation of AcSDKP (Fig. 4a). In order to identify the 
various peptidic fragments generated from T~4 through 
specific leavages, analyses were carried out in modified 
HPLC conditions (Fig. 4b). The isolated fragments 
were subjected to acid hydrolysis and analyzed for 
amino acid composition. This proved the formation of 
1-4, 13-23, 24-43, 21-31, 5-12 and 1-12 fragments 
through enzymatic cleavages of T~4. 
4. DISCUSSION 
Previous studies have demonstrated that the 
tetrapeptide AcSDKP is a new regulator of mammalian 
cell proliferation active in vivo on the hepatocytes and 
hematopoietic stem cells [1,2]. Biosynthesis tudies 
have shown that this factor is present in sera and in 
BMC, and biosynthesized in minute amounts [10]. The 
possibility that AcSDKP is formed through proteolytic 
maturation of a larger proteinous precursor appealed to 
us. According to a search in the Genomic Data Bank, 
rat phenylalanine hydroxylase, human and mouse 
Tumor Necrosis Factor ct, human retinal S-antigen, 
human amphiregulin and rat, porc, human and mouse 
T~4 are proteins claimed to contain the SDKP sequence 
in their structure. Except for this last protein, the SDKP 
sequence is included into the protein chains. A possible 
formation of AcSDKP from those hypothetical precur- 
sors would implicate three specific enzymatic reactions: 
two proteolytic leavages followed by one N-terminal 
acetylation. Conversely, a unique proteolytic leavage 
of the 4pro-SAsp peptidic bond of T/34 (Fig. 1) should 
be sufficient to form the active peptide from T~4 as the 
AcSDKP sequence constitutes the N-terminal part of 
this polypeptide. 
T~4 has been detected in numerous pecies as a cell 
component of various tissues [11,12], but its presence in 
32 

















I -  
3 
bJ n .  
6 
l i l t  I I  l i l l  l i  I I  I l l  t l  I l l  I l l  I I l l l  I I  I f  I f  I I  I I I I  I I I I I I I I I J i l l l l l l l l l  I I I I  I I I  I l l l l l l l l l l l l  l i l l l l  I I I I I  I I I  I I I  l i l i  i l l  I l l l  t i l l  I I  I I  I I I l l l l l  I I I I  
RETENTION TIME (rnin) 
Fig. 4. HPLC analysis of degradative peptides formed through T/~4 digestion by endopeptidase Asp-N. Analysis was performed: (a) On a Hypersil 
Cl8 column in 4.5°70 CH3CN, 0.1070 TFA, (A) AcSDKP standard l0 #g, (B) control initial time, (C) after an 18 h incubation. (b) After an 18 h 
incubation, peptides formed were separated on a Lichrospher 5/~m (4 × 250 mm) column with a linear gradient formed from 0.1 070 aqueous TFA 
and acetonitrile up to 40070 in 120 min. The isolated peptides were hydrolyzed in 6 M HCI for 60 min at 155°C. The amino acid composition of 
the generated fragments was determined by reverse phase HPLC after precolumn derivatization with o-phthalaldehyde/3-mercaptopropionic acid 
as described [9]. Identification of the following peptides is: 1, AcSDKP; 2, DKSKLKKTETQ; 3, EKNPLPSKETIEQEKQAQES; 4, ET- 
QEKNPLPSK; 5, DMAEIEKF; 6, AcSDKPDMAEIEKF. 
bone marrow has not been described until now. In a 
first set of experiments, mouse BMC extracts were 
analysed by HPLC. The presence in the HPLC spectra 
from mouse BMC extract (sample A, Fig. 2) of a peak 
identical to T/~4 which was shifted after oxidation to the 
elution time of T~4 sulfoxide, demonstrated the 
presence of TB4 in BMC. 
In a second set of experiments the formation of 
radiolabelled tetrapeptide by intact or lysed BMC en- 
zymatic systems through processing of a random 
tritiated [3HIT/34, in which about 10070 of the radioac- 
tivity is located in the AcSDKP N-terminal fragment, 
was investigated. With the aim of limiting a possible in- 
hibition of enzymatic degradative activity by AcSDKP 
already present in mouse BMC, [3HIT/34 was incubated 
with rabbit BMC preparations, which should be devoid 
of AcSDKP, as in this species, T~4 is replaced by the 
corresponding T/~4-gla nalogue, i.e. replacement of 
~Ser by tAla [11]. Incubations using intact BMC were 
carried out up to 18 h. The evaluation of the radioac- 
33 
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tivity associated with AcSDKP peptide demonstrated 
that BMC did contain an enzymatic system which was 
able to cleave T/34 and generate the tetrapeptide (Table 
I, Fig. 3). 
Several sets of  experiments howed that a maximal 
degradation was observed with intact or lysed cells after 
a 2 h incubation period. 
The stability of  [3H]AcSDKP observed under the 
same conditions of  incubation suggests that the small 
amount  of  AcSDKP released by enzymatic leavage of  
T~4 by BMC lysate cannot be attributed to the further 
degradation of  a neoformed tetrapeptide, and might 
suggest that the degradation products formed inhibit 
the enzymatic system implicated in their formation by a 
feedback control mechanism. This demonstrates that 
the apro-SAsp peptidic bond of T/~4 could be cleaved 
specifically by enzymatic activities present in BMC and 
lead to AcSDKP formation. 
Previous studies describe proteolytic degradations of  
T/34 using trypsin and thermolysin [3], but none of  those 
enzymes led to AcSDKP formation. In fact, two types 
of  enzymes were characterized in mammal ian tissues: 
the a-prolyl  endopeptidase [13] and the endoproteinase 
Asp-N [14-15] were possible candidates to carry out the 
observed cleavage. To determine if those enzymatic 
systems were effective, processing assays of  T~4 were 
conducted with the respective bacterial enzymes. 
Whereas a-prolyl-endopeptidase from Flavobacterium 
meningosepticum was unable to carry out T/34 process- 
ing, in spite of  the fact that we could demonstrate the 
presence of  such activity in BMC extracts (results not 
shown), endoproteinase Asp-N from Pseudomonas 
fragi cleaved specifically T/34 tO liberate AcSDKP (Fig. 
4). 
To our knowledge, until now the presence of  such an 
endoproteinase Asp-N activity in mammal ian system 
has been described only in monocyte membrane and 
was associated with the interleukine-1 maturat ion pro- 
cess [16-17]. The possibility that monocytes are involv- 
ed in AcSDKP formation is appealing since those cells 
are known to participate in the regulation of  the 
hematopoietic stem cell proliferation through cytokine 
secretion. Recently a new inhibitor of  the hematopoietic 
stem cell has been characterized as one of the secreted 
monokines [18]. This possibility does not exclude 
however the endoproteinase Asp-N might be present in 
other cells such as stroma cells, T or B lymphocytes 
which are known to interfere with the regulation of  
stem cell proliferation [19]. T~4 has been described as 
an immunoregulatory molecule. The possibility that a 
part of  those activities is due to a liberation of  AcSDKP 
might be questioned, as this molecule was shown to 
modulate T cell functions (unpublished results). 
The present demonstrat ion that AcSDKP can be 
generated in BMC from T~4, through a one-step 
maturat ion process involving endoproteinase Asp-N en- 
zymatic activity, does not exclude however the possibili- 
ty that this tetrapeptide might be derived in mam- 
malians through successive proteolytic leavages, either 
from T~4 or other SDKP containing proteins. 
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